NXL Nexalin Technology, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1527352 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY76.7%
TTM net income YoY-8.0%
TTM EPS YoY108.1%
Revenue 3-yr CAGR29.2%
Net income 3-yr CAGR—
Margins
Gross margin82.4%
Operating margin-3,386.0%
Net margin-3,380.6%
FCF margin—
EBITDA margin—
Returns
ROE-372.6%
ROA-222.9%
ROIC (approx.)-406.6%
Asset turnover0.07x
Leverage & solvency
Liabilities / assets92.0%
Debt / equity0.00x
Current ratio0.69x
Interest coverage-179.02x
Cash quality & payout
Operating cash flow / net income0.67x
Accruals ratio-74.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $78,301 | $12,161 | $14,950 | $171,895 | $18,149 | $70,588 | $41,015 | $27,179 |
| Cost of revenue | $22,620 | $3,264 | $1,817 | $21,029 | $3,948 | $22,838 | $13,558 | $7,496 |
| Gross profit | $55,681 | $8,897 | $13,133 | $150,866 | $14,201 | $47,750 | $27,457 | $19,683 |
| R&D expense | $219,834 | $564,480 | $346,382 | $224,940 | $226,520 | $225,774 | $406,288 | $737,241 |
| SG&A expense | $1.43M | $782,571 | $792,797 | $1.16M | $1.42M | $893,836 | $929,220 | $1.35M |
| Operating income | -$2.61M | -$2.25M | -$2.12M | -$2.41M | -$2.35M | -$1.62M | -$2.01M | -$2.88M |
| Interest expense | $52,771 | -$129 | -$34 | -$159 | -$2,288 | -$4,690 | -$1,103 | -$1,823 |
| Pretax income | -$2.66M | -$2.24M | -$2.10M | -$2.38M | -$2.28M | -$1.58M | -$1.99M | -$2.83M |
| Net income | -$2.66M | -$2.24M | -$2.10M | -$2.38M | -$2.28M | -$1.58M | -$1.99M | -$2.83M |
| EBITDA | -$2.57M | -$2.24M | -$2.12M | — | -$2.34M | — | — | — |
| EPS (basic) | -3.43 | -0.11 | -0.11 | — | -3.84 | -0.10 | -0.15 | — |
| EPS (diluted) | -3.43 | -0.11 | -0.11 | — | -3.84 | -0.10 | -0.15 | — |
| Weighted avg. shares (diluted) | 776,657 | 21.14M | 19.82M | — | 593,128 | 15.72M | 13.31M | — |
| Banking | ||||||||
| Net interest income | $52,771 | -$129 | -$34 | -$159 | -$2,288 | -$4,690 | -$1,103 | -$1,823 |
| Balance sheet | ||||||||
| Cash & equivalents | $793,139 | $1.00M | $1.21M | $654,783 | $590,075 | $431,320 | $622,029 | $574,485 |
| Short-term investments | — | — | $1.50M | $3.07M | $3.76M | $5.36M | $1.43M | $2.91M |
| Receivables | $118,285 | $52,930 | $43,004 | $81,571 | $7,925 | $59,841 | $14,479 | $13,043 |
| Inventory | $207,270 | $233,462 | $179,489 | $131,473 | $160,225 | $172,974 | $175,253 | $174,578 |
| Current assets | $1.89M | $1.86M | $3.29M | $4.30M | $4.82M | $6.27M | $2.62M | $3.96M |
| PP&E, net | $38,326 | $42,432 | — | — | — | — | — | — |
| Intangibles | — | $399,501 | $359,310 | $336,049 | $308,562 | $294,871 | $279,520 | $260,727 |
| Total assets | $3.29M | $3.00M | $3.69M | $4.64M | $5.13M | $6.56M | $2.90M | $4.22M |
| Current liabilities | $2.76M | $1.48M | $808,364 | $887,333 | $357,524 | $600,584 | $574,736 | $546,694 |
| Total liabilities | $3.02M | $1.48M | $808,364 | $887,333 | $357,524 | $600,584 | $574,736 | $546,694 |
| Shareholders' equity | $263,342 | $1.52M | $2.89M | $3.75M | $4.77M | $5.96M | $2.33M | $3.68M |
| Shares outstanding | 828,934 | 22.00M | 20.58M | 639,544 | 18.19M | 17.42M | 13.33M | 13.30M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.59M | -$1.80M | -$1.71M | -$1.15M | -$1.47M | -$917,165 | -$1.43M | -$1.13M |
| Investing cash flow | -$44,173 | $1.46M | $1.51M | $689,180 | $1.63M | -$3.92M | $1.47M | $1.63M |
| Financing cash flow | $1.42M | $138,365 | $756,421 | $523,550 | $0 | — | — | $0 |
| Depreciation & amortization | $36,866 | $2,738 | $4,106 | — | $5,473 | — | — | — |
| Stock-based compensation | $923,494 | $408,387 | $478,611 | $831,529 | $1.08M | $572,100 | $636,844 | $1.55M |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.